Project Grant R61HL180784
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $875K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $190,188 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a project grant titled "Fatty Acid Metabolic Drivers of Right Ventricular Dysfunction in Heart Failure Associated Pulmonary Hypertension." The award supports career development and mentored research for Dr. Jonah Garry to establish a patient-oriented translational research program focused on...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $776,005 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to fund research on beta-hydroxybutyrate–mediated endothelial cell and skeletal muscle dysfunction in pulmonary arterial hypertension. The project, R01HL184469, runs through May 31, 2031, with work performed in Baltimore, Maryland. The research addresses the mechanisms linking mitochondrial dysfunction in lung...
- The National Heart, Lung, and Blood Institute awarded $2.609 million to Vanderbilt University Medical Center on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathophysiological mechanisms of mitochondrial cyclophilin D acetylation in vascular dysfunction and hypertension through September 29, 2028. The project will define cell-specific pathogenic mechanisms of endothelial and smooth muscle cyclophilin D acetylation in hypertension and vascular...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Vanderbilt University Medical Center $341,280 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored career development project investigating apoptosis resistance mechanisms in pulmonary arterial smooth muscle cells. Dr. Niedermeyer, under mentorship from Dr. Larissa Shimoda and Dr. Mahendra Damarla, will conduct hands-on laboratory research, complete...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...
- The National Heart, Lung, and Blood Institute awarded Brown University $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of chitinase 3-like-1 in pulmonary arterial hypertension pathogenesis. The project grant funds research into how the protein CHI3L1 contributes to immune and metabolic dysfunction underlying vascular remodeling in PAH, with particular focus on macrophage metabolism and pro-remodeling effects. The research...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $264,750 on July 1, 2026, for a Project Grant (R03HL178552) under the Cardiovascular Diseases Research program (CFDA 93.837) to identify pathogenic somatic mutations in pulmonary arterial hypertension. The award funds research to determine whether somatic (acquired) mutations in disease-causing pathways contribute to PAH pathogenesis. The work proceeds through two approaches: analyzing cell-free DNA in circulating...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $856,721 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop flecainide analogs that selectively inhibit the cardiac ryanodine receptor (RYR2) for arrhythmia prevention. The project addresses a critical gap in antiarrhythmic therapy. Sudden cardiac death from ventricular arrhythmias accounts for 10–20 percent of adult deaths in the United States, and implantable...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $1.732 million on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop ENT-verticilide, a selective ryanodine receptor type 2 (RYR2) inhibitor, as a novel antiarrhythmic drug for atrial fibrillation treatment. The research addresses the clinical challenge that current antiarrhythmic therapies fail frequently due to heterogeneity in underlying causes of atrial...